All In Biotech

Drug Trial Radar · NCT07024797

Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants

A Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Chinese Subjects

Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Aug 21, 2025

Primary completion

Dec 8, 2025

Study completion Dec 8, 2025

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jun 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will assess the adverse events, tolerability, and how oral doses of ABBV-932 moves through the body in healthy adult Chinese participants.

Conditions

  • Healthy Volunteer

Interventions

  • ABBV-932Drug

    Oral Capsule

  • Placebo for ABBV-932Drug

    Oral Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax) of ABBV-932Time frame: Up to approximately 43 days
  2. Time to Cmax (Tmax) of ABBV-932Time frame: Up to approximately 43 days
  3. Observed plasma concentration at the end of a dosing interval (Ctrough) of ABBV-932Time frame: Up to approximately 43 days
  4. Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of Desmethyl Cariprazine ABBV-932Time frame: Up to approximately 43 days
  5. Maximum Plasma Concentration (Cmax) of DCARTime frame: Up to approximately 43 days
  6. Time to Cmax (Tmax) of DCARTime frame: Up to approximately 43 days
  7. Observed plasma concentration at the end of a dosing interval (Ctrough) of DCARTime frame: Up to approximately 43 days
  8. Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of Desmethyl Cariprazine (DCAR)Time frame: Up to approximately 43 days
  9. Maximum Plasma Concentration (Cmax) of Didesmethyl-Cariprazine (DDCAR)Time frame: Up to approximately 43 days
  10. Time to Cmax (Tmax) of DDCARTime frame: Up to approximately 43 days
  11. Observed plasma concentration at the end of a dosing interval (Ctrough) of DDCARTime frame: Up to approximately 43 days
  12. Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of DDCARTime frame: Up to approximately 43 days
  13. Number of Participants Experiencing Adverse EventsTime frame: Up to approximately 75 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Mental Health Center /ID# 273427

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.